News & Perspective

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE A seven-part series on the chances for immunizing the world against pandemic flu

Editor's note: This article was originally published in CIDRAP News as a seven-part series running from October 25 through November 2, 2007. It investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 31, 2007

Oct 31, 2007

THE PANDEMIC VACCINE PUZZLE Part 5: What role for prepandemic vaccination?

Editor's note: This is the fifth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Sep 27, 2007

Sep 27, 2007

Republic of Congo has monkeypox outbreak

(CIDRAP News) – More than 60 cases of monkeypox have been reported in the Republic of Congo since the beginning of this year, raising new concerns about the spread of the disease in humans.

Sep 04, 2007

Sep 04, 2007

FDA approves Acambis smallpox vaccine

(CIDRAP News) – A second-generation smallpox vaccine made by the British biotechnology company Acambis plc and stockpiled by the US government as protection against bioterrorist attacks has been approved by the US Food and Drug Administration (FDA).

Jun 18, 2007

Jun 18, 2007

FLU CONFERENCE COVERAGE New disease-control rules follow reminders of risks

– TORONTO (CIDRAP News) – Ten years after H5N1 avian influenza first began to raise fears of a potential pandemic, the world has a stronger set of tools to contain that virus and similar threats, but also a fresh awareness of humanity's vulnerability to fast-spreading diseases, experts said yesterday at an international conference on flu.

Jun 05, 2007

Jun 05, 2007

Danish firm wins US contract for new smallpox vaccine

(CIDRAP News) – US officials have announced the award of a $500 million contract to Bavarian Nordic A/S, a Danish firm, for 20 million doses of a smallpox vaccine that's expected to be safe for people with weakened immune systems.

May 29, 2007

May 29, 2007

Airline trips by resistant-TB patient trigger alert

(CIDRAP News) – In a rare action, federal health authorities have ordered an Atlanta man who has extensively drug-resistant tuberculosis (XDR TB) into isolation and are looking for people who recently flew with him so they can be tested for the disease.

May 18, 2007

May 18, 2007

WHO postpones smallpox virus destruction by 4 years

(CIDRAP News) – At the World Health Assembly meeting today in Geneva, global health officials agreed to postpone for 4 years a decision on when to destroy the world's remaining stores of smallpox virus.

May 18, 2007

FDA panel recommends smallpox vaccine approval

(CIDRAP News) – A US Food and Drug Administration (FDA) panel yesterday recommended that the agency approve a smallpox vaccine made by British biotechnology company Acambis plc that is currently being stockpiled for the US government.

Pages

Sort Results

 

Narrow results

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»